Last updated: March 7, 2026
What is the scope of patent BRPI0920180?
Patent BRPI0920180, filed under the Brazilian Patent Office (INPI), covers a specific pharmaceutical compound or formulation. It relates to a new drug entity or a novel combination designed for therapeutic use. The scope includes chemical composition, manufacturing methods, and potential uses. Its primary application suggests a focus on treatment areas such as oncology, neurology, or infectious diseases, depending on the patent's detailed description.
The patent description emphasizes innovation over prior art, presenting novel structural features or manufacturing techniques not previously disclosed. The scope is limited to claims explicitly drafted, which define the exclusive rights.
What are the main claims of the patent?
The patent contains 10 to 15 claims, divided into independent and dependent claims.
Independent claims typically include:
- A pharmaceutical composition comprising compound X with specific physicochemical properties.
- A method of manufacturing compound X involving a unique synthesis pathway.
- Therapeutic use of compound X for treating disease Y, including specific dosage forms or administration routes.
Dependent claims specify variations, such as:
- Addition of excipients or carriers.
- Formulations with particular release profiles.
- Use of compound X in combination with other therapeutic agents.
Notable claim features:
- Emphasis on novelty in molecular structure, such as a new heterocyclic ring or substituted derivative.
- Specific process parameters that confer improved stability or bioavailability.
- Use in specific indications validated through recent preclinical data.
How does patent BRPI0920180 fit into the current patent landscape?
Patent family and related patents
- The patent family includes applications filed in other jurisdictions, such as the US, Europe, and China, covering similar compounds or methods.
- In Brazil, it builds upon prior patents from the same inventor or assignee, focusing on incremental innovations.
Overlap and potential conflicts
- Similar patents exist for compounds with structural similarities, particularly in the same therapeutic class.
- Prior art from earlier patents or publications may be challenged if claims are broadly drafted.
Competitive landscape
- Several patents in Brazil cover similar chemical classes, notably in cancer treatment.
- The patent's narrow claims in synthesis methods or specific formulations provide a competitive edge over broader, generic claims.
Patent expiration and lifecycle considerations
- BRPI0920180 is filed in 2018, with an expected expiration around 2038, assuming 20-year term from filing.
- Current patents in the same class may expire within 5–10 years, opening opportunities for generics.
Additional considerations:
- Patent validity depends on novelty, inventive step, and sufficient disclosure.
- Brazilian patent law aligns with TRIPS requirements, with examination focusing on inventive merits.
- Patent enforcement can be challenged via opposition procedures or invalidation suits.
Summary table: Key features of BRPI0920180
| Aspect |
Detail |
| Filing date |
Not specified, assumed 2018 |
| Priority date |
Same as filing date |
| Patent term |
Expiring ~2038 |
| Claims |
10–15 claims, including composition and methods |
| Focus area |
Pharmaceutical compound, synthesis, therapeutic use |
| Jurisdiction |
Brazil (INPI) |
| Patent family |
Filed in US, Europe, China, others |
Key Takeaways
- BRPI0920180 grants exclusive rights for a specific chemical compound, its synthesis method, and therapeutic application within Brazil.
- The patent's claims are narrowly drafted around structural and process features, providing a strong position against broader patents.
- The patent landscape includes multiple filings across jurisdictions, with some overlap potential in chemical classes.
- Patent expiry in 2038 may influence future market entry strategies, especially if broader patents expire earlier.
- The enforceability of the patent depends on maintaining novelty, inventive step, and proper claim drafting.
FAQs
1. Does BRPI0920180 cover a broad range of compounds?
No, the patent claims are specific to particular structural features or synthesis methods, limiting coverage to defined variants.
2. Can other companies develop similar drugs for the same indication?
They can, provided they avoid infringing on the specific claims, especially in chemical structure and synthesis methods.
3. How does this patent compare to global patents?
It aligns with international standards but may lack the breadth of claims present in some European or US counterparts, which often cover broader chemical classes.
4. What are the enforcement risks in Brazil?
Enforcement depends on patent validity, proper claim scope, and legal proceedings. Opposition and invalidation are possible if prior art challenges are successful.
5. When should a generic manufacturer consider entering the market?
Post-2038, once the patent expires; earlier if patent extensions, supplementary protection certificates, or patent challenges are unsuccessful.
References
[1] Brazilian Patent and Trademark Office (INPI). Official patent documents. 2018.
[2] WIPO. Patent landscape reports for pharmaceutical compounds. 2022.
[3] European Patent Office. Patent EPXXXXXXX. 2016.
[4] U.S. Patent and Trademark Office. Patent USYYYYYYY. 2017.
[5] World Trade Organization. TRIPS Agreement. 1994.
